Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00037681.xml
CC BY-NC-ND 4.0 · J Neuroanaesth Crit Care 2016; 03(03): 245-248
DOI: 10.4103/2348-0548.190071
DOI: 10.4103/2348-0548.190071
Case Report
Does ‘heparin-induced thrombocytopenia’ hit our minds?
Further Information
Publication History
Publication Date:
05 May 2018 (online)
Abstract
Unfractionated heparin is a widely used drug to prevent deep vein thrombosis and pulmonary emboli in patients at risk. With the advent of newer anticoagulants having lesser side effects, its use has diminished but not out of service. Here, we report a case of deep venous thrombosis, in a patient on prophylactic dose of heparin, which was later found to be a manifestation of heparin-induced thrombocytopenia (HIT). Thrombosis in the presence of heparin prophylaxis should be considered as HIT rather than a failure of anticoagulation.
-
REFERENCES
- 1 Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A. et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: Analysis of the MEDENOX study. Arch Intern Med 2004; 164: 963-8
- 2 Qaseem A, Snow V, Barry P, Hornbake ER, Rodnick JE, Tobolic T. et al. Current diagnosis of venous thromboembolism in primary care: A clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 2007; 146: 454-8
- 3 Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J. et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003; 349: 1227-35
- 4 Warkentin TE, Greinacher A, Koster A, Lincoff AM. American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133 (Suppl. 06) Suppl 340S-80S
- 5 Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S. et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (Suppl. 02) Suppl e495S-530S
- 6 Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest 2007; 131: 1644-9
- 7 Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006; 108: 2937-41
- 8 Shantsila E, Lip GY, Chong BH. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest 2009; 135: 1651-64
- 9 Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4: 759-65